PriceTargets.com logo

Hims & Hers Health - HIMS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $36.92
  • Forecasted Upside: -9.92%
  • Number of Analysts: 13
  • Breakdown:
  • 2 Sell Ratings
  • 8 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$40.98 As of 05/2/2025 04:59 PM ET
▲ +4.82 (13.33%)

This chart shows the closing price for HIMS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$40.98Closing price on 05/03/25:
Get New Hims & Hers Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HIMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HIMS

Analyst Price Target is $36.92
▼ -9.92% Downside Potential
This price target is based on 13 analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is $36.92, with a high forecast of $68.00 and a low forecast of $23.00. The average price target represents a -9.92% upside from the last price of $40.98.

This chart shows the closing price for HIMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
5/247/2410/241/255/255/26$7.87$25$42$59$76Closing price on 05/03/25: $40.98High$68.00Average$36.92Low$23.00




Current Consensus is Hold

The current consensus among 13 contributing investment analysts is to hold stock in Hims & Hers Health. This rating has held steady since November 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/10/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/8/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
2/2/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
4/3/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 2 sell ratings
Ratings as of
5/3/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/29/2025Bank of AmericaBoost TargetUnderperform ➝ Underperform$22.00 ➝ $26.00
4/29/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$60.00 ➝ $40.00
4/29/2025TD CowenDowngradeBuy ➝ Hold$44.00 ➝ $30.00
4/25/2025CitigroupLower TargetSell ➝ Sell$27.00 ➝ $25.00
4/10/2025Truist FinancialLower TargetHold ➝ Hold$39.00 ➝ $33.00
4/2/2025CitigroupReiterated RatingSell ➝ Sell
3/18/2025Bank of AmericaBoost TargetUnderperform ➝ Underperform$21.00 ➝ $22.00
3/6/2025Bank of AmericaReiterated RatingUnderperform ➝ Underperform$21.00 ➝ $21.00
3/6/2025CitigroupReiterated RatingSell ➝ Sell$27.00 ➝ $27.00
2/26/2025Truist FinancialBoost TargetHold ➝ Hold$24.00 ➝ $39.00
2/25/2025Leerink PartnersBoost TargetMarket Perform ➝ Market Perform$24.00 ➝ $40.00
2/25/2025Piper SandlerBoost TargetNeutral ➝ Neutral$24.00 ➝ $35.00
2/25/2025CitigroupBoost TargetSell ➝ Sell$25.00 ➝ $27.00
2/25/2025Needham & Company LLCBoost TargetBuy ➝ Buy$31.00 ➝ $61.00
2/20/2025Bank of AmericaBoost TargetUnderperform ➝ Underperform$18.00 ➝ $21.00
2/19/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$38.00 ➝ $68.00
2/18/2025Morgan StanleyDowngradeOverweight ➝ Equal Weight$42.00 ➝ $60.00
1/10/2025CitigroupDowngradeNeutral ➝ Sell$24.00 ➝ $25.00
1/7/2025BTIG ResearchInitiated CoverageBuy$35.00
1/6/2025Piper SandlerBoost TargetNeutral ➝ Neutral$21.00 ➝ $24.00
1/6/2025Needham & Company LLCBoost TargetBuy ➝ Buy$28.00 ➝ $31.00
12/17/2024Morgan StanleyInitiated CoverageOverweight$42.00
12/2/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$28.00 ➝ $38.00
11/20/2024TD CowenReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
11/14/2024Bank of AmericaDowngradeBuy ➝ Underperform$32.00 ➝ $18.00
11/8/2024TD CowenBoost TargetBuy ➝ Buy$25.00 ➝ $28.00
11/6/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$23.00 ➝ $27.00
11/5/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.00
11/5/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$24.00 ➝ $28.00
10/21/2024Bank of AmericaBoost TargetBuy ➝ Buy$23.00 ➝ $25.00
10/14/2024Bank of AmericaBoost TargetBuy ➝ Buy$20.00 ➝ $23.00
9/13/2024Bank of AmericaLower TargetBuy ➝ Buy$24.00 ➝ $20.00
8/22/2024Needham & Company LLCInitiated CoverageBuy$24.00
8/9/2024Imperial CapitalDowngradeOutperform ➝ In-Line
8/7/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$16.00 ➝ $23.00
8/6/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$18.00 ➝ $18.00
7/18/2024Truist FinancialBoost TargetHold ➝ Hold$13.00 ➝ $23.00
7/11/2024TD CowenBoost TargetBuy ➝ Buy$15.00 ➝ $25.00
7/11/2024Piper SandlerBoost TargetNeutral ➝ Neutral$16.00 ➝ $18.00
6/27/2024Jefferies Financial GroupBoost TargetHold ➝ Hold$14.00 ➝ $23.00
6/13/2024Bank of AmericaBoost TargetBuy ➝ Buy$22.00 ➝ $26.00
6/3/2024Bank of AmericaBoost TargetBuy ➝ Buy$17.25 ➝ $22.00
5/22/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$20.00 ➝ $24.00
5/22/2024CitigroupDowngradeBuy ➝ Neutral$16.00 ➝ $20.00
5/7/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$14.00 ➝ $16.00
5/7/2024Piper SandlerBoost TargetNeutral ➝ Neutral$11.00 ➝ $13.00
4/26/2024Seaport Res PtnReiterated RatingBuy
4/16/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$17.00 ➝ $15.00
4/10/2024Canaccord Genuity GroupInitiated CoverageBuy$20.00
4/10/2024Canaccord Genuity GroupInitiated CoverageBuy$20.00
2/28/2024Imperial CapitalUpgradeIn-Line ➝ Outperform$16.00
2/27/2024CitigroupBoost TargetBuy ➝ Buy$12.00 ➝ $16.00
2/27/2024GuggenheimBoost TargetBuy ➝ Buy$15.00 ➝ $17.00
2/27/2024Piper SandlerBoost TargetNeutral ➝ Neutral$9.00 ➝ $11.00
2/27/2024Truist FinancialBoost TargetHold ➝ Hold$10.00 ➝ $13.00
2/26/2024Leerink PartnrsReiterated RatingMarket Perform
2/26/2024Leerink PartnersInitiated CoverageMarket Perform$10.00
1/5/2024Tigress FinancialBoost TargetBuy ➝ Buy$14.00 ➝ $15.00
12/7/2023Imperial CapitalInitiated CoverageInline$9.00
8/9/2023Truist FinancialLower TargetHold ➝ Hold$12.00 ➝ $10.00
8/8/2023Piper SandlerLower Target$11.00 ➝ $10.00
8/8/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$14.00
7/28/2023TD CowenInitiated CoverageOutperform$11.00
6/15/2023Tigress FinancialBoost Target$12.00 ➝ $14.00
5/30/2023Piper SandlerLower Target$12.00 ➝ $11.00
5/9/2023Bank of AmericaBoost Target$13.50 ➝ $15.00
5/9/2023Piper SandlerBoost Target$11.00 ➝ $12.00
4/27/2023GuggenheimBoost Target$15.00 ➝ $18.00
4/26/2023Piper SandlerBoost Target$10.00 ➝ $11.00
4/11/2023Robert W. BairdInitiated CoverageNeutral$10.00
3/1/2023Deutsche Bank AktiengesellschaftBoost Target$7.00 ➝ $9.00
3/1/2023Credit Suisse GroupBoost TargetOutperform$8.00 ➝ $14.00
2/28/2023GuggenheimReiterated RatingBuy$15.00
2/28/2023Truist FinancialBoost TargetHold$7.00 ➝ $12.00
2/28/2023Piper SandlerBoost TargetNeutral$7.00 ➝ $10.00
2/28/2023Bank of AmericaBoost TargetBuy$11.50 ➝ $13.50
2/28/2023CitigroupBoost TargetBuy$9.00 ➝ $14.00
2/9/2023Jefferies Financial GroupUpgradeHold ➝ Buy$7.00 ➝ $11.00
1/10/2023Tigress FinancialBoost Target$11.00 ➝ $12.00
1/3/2023Piper SandlerBoost Target$6.00 ➝ $7.00
11/15/2022CitigroupBoost Target$8.00 ➝ $9.00
11/8/2022Leerink PartnersUpgradeMarket Perform ➝ Outperform$5.00
11/8/2022Bank of AmericaUpgradeNeutral ➝ Buy$7.50 ➝ $8.50
10/17/2022Piper SandlerDowngradeOverweight ➝ Neutral$8.00 ➝ $6.00
9/7/2022Truist FinancialInitiated CoverageHold$7.00
8/15/2022GuggenheimBoost Target$12.00
8/10/2022Deutsche Bank AktiengesellschaftBoost Target$7.00 ➝ $8.00
8/10/2022Credit Suisse GroupBoost TargetOutperform$7.00 ➝ $8.00
8/9/2022Leerink PartnersBoost TargetUnderperform$4.00 ➝ $5.00
7/15/2022Leerink PartnersInitiated CoverageUnderperform$4.00
5/26/2022Piper SandlerLower TargetOverweight$8.00 ➝ $6.00
5/10/2022CitigroupLower Target$9.00 ➝ $6.00
4/13/2022GuggenheimInitiated CoverageBuy$10.00
3/10/2022Deutsche Bank AktiengesellschaftInitiated CoverageHold$7.00
2/23/2022Piper SandlerLower Target$12.00 ➝ $8.00
12/20/2021CitigroupLower TargetBuy$14.00 ➝ $9.00
12/1/2021Jefferies Financial GroupInitiated CoverageHold$7.00
11/11/2021Piper SandlerUpgradeNeutral ➝ Overweight$10.00 ➝ $12.00
7/6/2021Bank of AmericaInitiated CoverageNeutral$12.00
5/26/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform
5/20/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$16.00
5/19/2021CitigroupBoost TargetBuy$16.00 ➝ $20.00
4/21/2021Truist FinancialInitiated CoverageHold
3/19/2021Piper SandlerLower TargetNeutral$20.00 ➝ $18.00
3/9/2021Credit Suisse GroupInitiated CoverageNeutral$16.00
3/2/2021CitigroupUpgradeNeutral ➝ Buy$23.00
2/17/2021CitigroupInitiated CoverageNeutral$23.00
2/12/2021Piper SandlerInitiated CoverageNeutral$20.00
2/8/2021Tigress FinancialInitiated CoverageBuy
(Data available from 5/4/2020 forward)

News Sentiment Rating

1.06 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 34 very positive mentions
  • 16 positive mentions
  • 11 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2024
  • 30 very positive mentions
  • 32 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2024
  • 55 very positive mentions
  • 42 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2024
  • 32 very positive mentions
  • 20 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
1/4/2025
  • 37 very positive mentions
  • 30 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2025
  • 92 very positive mentions
  • 86 positive mentions
  • 28 negative mentions
  • 2 very negative mentions
Mentions as of
3/5/2025
  • 66 very positive mentions
  • 46 positive mentions
  • 12 negative mentions
  • 2 very negative mentions
Mentions as of
4/4/2025
  • 77 very positive mentions
  • 40 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2025

Current Sentiment

  • 77 very positive mentions
  • 40 positive mentions
  • 8 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Hims & Hers Health logo
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Read More

Today's Range

Now: $40.98
Low: $36.62
High: $41.09

50 Day Range

MA: $32.21
Low: $25.41
High: $45.20

52 Week Range

Now: $40.98
Low: $11.45
High: $72.98

Volume

49,512,288 shs

Average Volume

16,802,829 shs

Market Capitalization

$9.10 billion

P/E Ratio

93.14

Dividend Yield

N/A

Beta

1.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Hims & Hers Health?

The following Wall Street research analysts have issued stock ratings on Hims & Hers Health in the last year: Bank of America Co., BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Deutsche Bank Aktiengesellschaft, Imperial Capital, Jefferies Financial Group Inc., Leerink Partners, Morgan Stanley, Needham & Company LLC, Piper Sandler, TD Cowen, and Truist Financial Co..
View the latest analyst ratings for HIMS.

What is the current price target for Hims & Hers Health?

0 Wall Street analysts have set twelve-month price targets for Hims & Hers Health in the last year. Their average twelve-month price target is $36.92, suggesting a possible downside of 9.9%. Canaccord Genuity Group Inc. has the highest price target set, predicting HIMS will reach $68.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $23.00 for Hims & Hers Health in the next year.
View the latest price targets for HIMS.

What is the current consensus analyst rating for Hims & Hers Health?

Hims & Hers Health currently has 2 sell ratings, 8 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HIMS, but not buy more shares or sell existing shares.
View the latest ratings for HIMS.

What other companies compete with Hims & Hers Health?

Other companies that are similar to Hims & Hers Health include Natera, Fresenius Medical Care, Guardant Health, Option Care Health and RadNet. Learn More about companies similar to Hims & Hers Health.

How do I contact Hims & Hers Health's investor relations team?

Hims & Hers Health's physical mailing address is 2269 CHESTNUT STREET SUITE 523, SAN FRANCISCO CA, 94123. The company's listed phone number is 415-851-0195 and its investor relations email address is hims-ir@westwicke.com. The official website for Hims & Hers Health is www.forhims.com. Learn More about contacing Hims & Hers Health investor relations.





Receive Hims & Hers Health News & Ratings Daily
Sign up to receive the latest news and ratings for Hims & Hers Health and its competitors with PriceTargets.com’s free daily newsletter.